The past Faxletter issue was 119, not 120 as was mentioned on the web and we apologize for this mistake. The new faxletter was posted a few minutes ago. It revolves around pharmacogenomics. The fax gives a hint about the technology and how it must be assessed. The fax starts by telling the story of Sepracor and then assesses the chiral technology and the firms that conduct it.
Subscribers can go now to member's area and read it.
Prohost is an independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk.